474 assets in Plasma Cell Myeloma

Therapeutic assets addressing Plasma Cell Myeloma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Infliximab Plasma Cell Myeloma	Naresh Bumma	P2	CCC (51)
Ogalvibart Plasma Cell Myeloma	Imperial College Healthcare NHS Trust	P2	CCC (51)
Apsolol Plasma Cell Myeloma	GPCR Therapeutics, Inc.	P2	CCC (50)
Elraglusib Plasma Cell Myeloma	Actuate Therapeutics Inc.	P2	CCC (50)
Bcd-248 Plasma Cell Myeloma	Biocad	P2	CCC (49)
gc012f Plasma Cell Myeloma	Gracell Biotechnologies (Shanghai) Co., Ltd.	P1/2	CCC (49)
il-15-armored car-t cells Plasma Cell Myeloma	The First Hospital of Jilin University	P2	CCC (49)
Allogeneic Anti-Ny-Eso-1-Tcr-Il-15-Transduced Cord Blood-Derived Natural Killer Cells Plasma Cell Myeloma	M.D. Anderson Cancer Center	P1/2	CCC (48)
Anitocabtagene-Autoleucel Plasma Cell Myeloma	Kite, A Gilead Company	P2	CCC (48)
Bcd-264 Plasma Cell Myeloma	Biocad	P3	CCC (48)
Boclatixafortide Plasma Cell Myeloma	University Health Network, Toronto	P2	CCC (48)
Catequentinib Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (48)
C-Car088 Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (48)
CD47/SIRPA-BLOCKING AGENT ALX148 Plasma Cell Myeloma	Sanofi	P1/2	CCC (48)
Cemsidomide Plasma Cell Myeloma	C4 Therapeutics, Inc.	P2	CCC (48)
Ciltacabtagene Autoleucel Plasma Cell Myeloma	Medical College of Wisconsin	P2	CCC (48)
Colchicinum Plasma Cell Myeloma	Affiliated Hospital of Nantong University	P3	CCC (48)
Cytokine-Treated Veto Cells Plasma Cell Myeloma	M.D. Anderson Cancer Center	P1/2	CCC (48)
Equecabtagene Autoleucel Plasma Cell Myeloma	Nanjing IASO Biotechnology Co., Ltd.	P3	CCC (48)
Grastofil Plasma Cell Myeloma	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	P3	CCC (48)
hul001 Plasma Cell Myeloma	HuniLife Biotechnology, Inc.	P1/2	CCC (48)
Human Bcma Targeted T Cells Plasma Cell Myeloma	Hrain Biotechnology Co., Ltd.	P2	CCC (48)
Icp-490 Plasma Cell Myeloma	Beijing InnoCare Pharma Tech Co., Ltd.	P1/2	CCC (48)
Idecabtagene Vicleucel Plasma Cell Myeloma	St. Olavs Hospital	P3	CCC (48)
Inobrodib Plasma Cell Myeloma	CellCentric Ltd.	P2	CCC (48)
Iopofosine (¹³¹I) Plasma Cell Myeloma	Cellectar Biosciences, Inc.	P2	CCC (48)
Lapelga Plasma Cell Myeloma	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	P3	CCC (48)
Linperlisib Plasma Cell Myeloma	Fuling Zhou	P1/2	CCC (48)
Moderna Bivalent Mrna Vaccine Plasma Cell Myeloma	Monash University	P3	CCC (48)
Narazaciclib Plasma Cell Myeloma	Adriana Rossi	P1/2	CCC (48)
Narlumosbart Plasma Cell Myeloma	RenJi Hospital	P3	CCC (48)
Olanzapine Plasma Cell Myeloma	The Affiliated People's Hospital of Ningbo University	P3	CCC (48)
Olaparib Plasma Cell Myeloma	Medical College of Wisconsin	P2	CCC (48)
Oxycodone Plasma Cell Myeloma	Memorial Sloan Kettering Cancer Center	P3	CCC (48)
Oxycodone Hydrochloride, Hydrocodone- Plasma Cell Myeloma	St. Louis University	P3	CCC (48)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Plasma Cell Myeloma	Multiple Myeloma Research Consortium	P2	CCC (48)
Pegenzileukin Plasma Cell Myeloma	Sanofi	P1/2	CCC (48)
Pertuzumab Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (48)
Pfizer Bivalent Covid-19 Vaccine Plasma Cell Myeloma	Monash University	P3	CCC (48)
Purinostat Plasma Cell Myeloma	Chengdu Zenitar Biomedical Technology Co., Ltd	P1/2	CCC (48)
Regn17372 Plasma Cell Myeloma	Regeneron Pharmaceuticals	P1/2	CCC (48)
Regorafenib Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (48)
Relatlimab Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CCC (48)
Trastuzumab Emtansine Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (48)
Tropisetron Plasma Cell Myeloma	The Affiliated People's Hospital of Ningbo University	P3	CCC (48)
Tucidinostat Plasma Cell Myeloma	The First Affiliated Hospital of Soochow University	P2	CCC (48)
Vismodegib Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (48)
Anti-Tgf-Beta Monoclonal Antibody Sar-439459 Plasma Cell Myeloma	Sanofi	P1/2	CC (47)
Autologous Bcma/Cd19 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Bcma/Cd38 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)

Showing 151 to 200 of 474 assets

PreviousPage 4 of 10Next